https://www.selleckchem.com/pr....oducts/bms-345541.ht
The purpose of this study was to measure genomic changes that emerge with enzalutamide treatment using analyses of whole-genome sequencing and RNA sequencing. One hundred and one tumors from men with metastatic castration-resistant prostate cancer (mCRPC) who had not been treated with enzalutamide ( = 64) or who had enzalutamide-resistant mCRPC ( = 37) underwent whole genome sequencing. Ninety-nine of these tumors also underwent RNA sequencing. We analyzed the genomes and transcriptomes of these mCRPC tumors. Copy number loss was mor
إعجاب
علق
شارك
